|
1
|
Fandy TE: Development of DNA
methyltransferase inhibitors for the treatment of neoplastic
diseases. Curr Med Chem. 16:2075–2085. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Ng HH, Erdjument-Bromage H,
Tempst P, Bird A and Reinberg D: Analysis of the NuRD subunits
reveals a histone deacetylase core complex and a connection with
DNA methylation. Genes Dev. 13:1924–1935. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prokhortchouk A, Hendrich B, Jørgensen H,
Ruzov A, Wilm M, Georgiev G, Bird A and Prokhortchouk E: The p120
catenin partner Kaiso is a DNA methylation-dependent
transcriptional repressor. Genes Dev. 15:1613–1618. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bird AP: The relationship of DNA
methylation to cancer. Cancer Surv. 28:87–101. 1996.PubMed/NCBI
|
|
5
|
Bird A: DNA methylation de novo. Science.
286:2287–2288. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dammann R, Li C, Yoon JH, Chin PL, Bates S
and Pfeifer GP: Epigenetic inactivation of a RAS association domain
family protein from the lung tumour suppressor locus 3p21.3. Nat
Genet. 25:315–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dammann R, Takahashi T and Pfeifer GP: The
CpG island of the novel tumor suppressor gene RASSF1A is intensely
methylated in primary small cell lung carcinomas. Oncogene.
20:3563–3567. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartling B, Hoffmann J, Holtz J, Schulz R,
Heusch G and Darmer D: Quantification of cardioprotective gene
expression in porcine short-term hibernating myocardium. J Mol Cell
Cardiol. 31:147–158. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burbee DG, Forgacs E, Zöchbauer-Müller S,
Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S,
et al: Epigenetic inactivation of RASSF1A in lung and breast
cancers and malignant phenotype suppression. J Natl Cancer Inst.
93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piekarz RL and Bates SE: Epigenetic
modifiers: basic understanding and clinical development. Clin
Cancer Res. 15:3918–3926. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wijermans P, Lubbert M, Verhoef G, Bosly
A, Ravoet C, Andre M and Ferrant A: Low-dose
5-Aza-2′-deoxycytidine, a DNA hypomethylation agent for the
treatment of high-risk myelodyspastic syndrome: a multicenter phase
II study in elderly patients. J Clin Oncol. 18:956–960.
2000.PubMed/NCBI
|
|
12
|
Xhu XJ and Dai DQ: Epigenetics and
gastrointestinal cancer. Chin J Digest. 14:3215–3256. 2006.
|
|
13
|
Tomita H, Hirata A, Yamada Y, Hata K,
Oyama T, Mori H, Yamashita S, Ushijima T and Hara A: Suppressive
effect of global DNA hypomethylation on gastrc carcinogenesis.
Carcinogenesis. 31:1627–1633. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zöchbauer-Müller S, Fong KM, Virmani AK,
Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of
multiple genes in non-small cell lung cancers. Cancer Res.
61:249–255. 2001.PubMed/NCBI
|
|
15
|
Daskalakis M, Nguyen TT, Nguyen C,
Guldberg P, Köhler G, Wijermans P, Jones PA and Lübbert M:
Demethylation of a hypermethylated P15/INK4B gene in patients with
myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine)
treatment. Blood. 100:2957–2964. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bae SI, Lee HS, Kim SH and Kim WH:
Inactivation of O6-methylguanine-DNA methyltransferase by promoter
CpG island hypermethylation in gastric cancers. Br J Cancer.
86:1888–1892. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Esteller M, Corn PG, Baylin SB and Herman
JG: A gene hypermethylation profile of human cancer. Cancer Res.
61:3225–3229. 2001.PubMed/NCBI
|
|
18
|
Lübbert M, Tobler A and Daskalakis M:
Cytosine demethylation of the proteinase-3/myeloblastin primary
granule protease gene during phagocyte development. Leukemia.
13:1420–1427. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim SH, Bae SI, Lee HS and Kim WH:
Alteration of O6-methylguanine-DNA methyltransferase in
colorectal neoplasms in sporadic and familial adenomatous polyposis
patients. Mol Carcinog. 37:32–38. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bender CM, Pao MM and Jones PA: Inhibition
of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth
of human tumor cell lines. Cancer Res. 58:95–101. 1998.PubMed/NCBI
|
|
21
|
Gonzalgo ML, Hayashida T, Bender CM, Pao
MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT and Jones PA: The
role of DNA methylation in expression of the p19/p16 locus in human
bladder cancer cell lines. Cancer Res. 58:1245–1252.
1998.PubMed/NCBI
|
|
22
|
Xiong Z, Wu AH, Bender CM, Tsao JL, Blake
C, Shibata D, Jones PA, Yu MC, Ross RK and Laird PW: Mismatch
repair deficiency and CpG island hypermethylation in sporadic colon
adenocarcinomas. Cancer Epidemiol Biomarkers Prev. 10:799–803.
2001.PubMed/NCBI
|
|
23
|
Dammann R, Schagdarsurengin U, Strunnikova
M, Rastetter M, Seidel C, Liu L, Tommasi S and Pfeifer GP:
Epigenetic inactivation of the Ras-association domain family 1
(RASSF1A) gene and its function in human carcinogenesis. Histol
Histopathol. 18:665–677. 2003.PubMed/NCBI
|
|
24
|
Liu L, Tommasi S, Lee DH, Dammann R and
Pfeifer GP: Control of microtubule stability by the RASSF1A tumor
suppressor. Oncogene. 22:8125–8136. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Strunnikova M, Schagdarsurengin U, Kehlen
A, Garbe JC, Stampfer MR and Dammann R: Chromatin inactivation
precedes de novo DNA methylation during the progressive epigenetic
silencing of the RASSF1A promoter. Mol Cell Biol. 25:3923–3933.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chow LS, Lo KW, Kwong J, To KF, Tsang KS,
Lam CW, Dammann R and Huang DP: RASSF1A is a target tumor
suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer.
109:839–847. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tommasi S, Dammann R, Zhang Z, Wang Y, Liu
L, Tsark WM, Wilczynski SP, Li J, You M and Pfeifer GP: Tumor
susceptibility of Rassf1a knockout mice. Cancer Res. 65:92–98.
2005.PubMed/NCBI
|
|
28
|
Lee S, Hwang KS, Lee HJ, Kim JS and Kang
GH: Aberrant CpG island hypermethylation of multiple genes in
colorectal neoplasia. Lab Invest. 87:884–893. 2004. View Article : Google Scholar
|
|
29
|
Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH
and Kim JS: Aberrant CpG island hypermethylation of chronic
gastritis, in relation to aging, gender, intestinal metaplasia, and
chronic inflammation. Am J Pathol. 163:1551–1556. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuroki T, Trapasso F, Yendamuri S,
Matsuyama A, Alder H, Mori M and Croce CM: Allele loss and promoter
hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor
suppressor genes on chromosome 3p in esophageal squamous cell
carcinoma. Cancer Res. 63:3724–3728. 2003.PubMed/NCBI
|
|
31
|
Kuroki T, Trapasso F, Yendamuri S,
Matsuyama A, Alder H, Mori M and Croce CM: Promoter
hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
Clin Cancer Res. 9:1441–1445. 2003.PubMed/NCBI
|
|
32
|
Byun DS, Lee MG, Chae KS, Ryu BG and Chi
SG: Frequent epigenetic inactivation of RASSF1A by aberrant
promoter hypermethylation in human gastric adenocarcinoma. Cancer
Res. 61:7034–7038. 2001.PubMed/NCBI
|
|
33
|
Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH,
Kim JI, Chang SG and Chi SG: Frequent epigenetic inactivation of
RASSF1A in human bladder carcinoma. Cancer Res. 61:6688–6692.
2001.PubMed/NCBI
|
|
34
|
Chan MW, Chan LW, Tang NL, Lo KW, Tong JH,
Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM, et al: Frequent
hypermethylation of promoter region of RASSF1A in tumor tissues and
voided urine of urinary bladder cancer patients. Int J Cancer.
104:611–616. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Müller HM, Widschwendter A, Fiegl H,
Ivarsson L, Goebel G, Perkmann E, Marth C and Widschwendter M: DNA
methylation in serum of breast cancer patients: an independent
prognostic marker. Cancer Res. 63:7641–7645. 2003.PubMed/NCBI
|
